Minimizing repolarization-Related proarrhythmic risk in drug development and clinical practice

Drugs

Volumn 70, Issue 5, 2010, Pages 573-603

  Farkas, Attila S ^a   Nattel, Stanley ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; ENCAINIDE; FLECAINIDE; FLUNARAZINE; HALOTHANE; ISOFLURANE; KETOCONAZOLE; LEMAKALIM; LIDOCAINE; MALLOTOXIN; METHOXAMINE; MEXILETINE; MORACIZINE; NICORANDIL; NISOLDIPINE; NS 1643; PD 118057; PENTOBARBITAL; PHARMACOLOGICAL BIOMARKER; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL STIMULATING AGENT; PROPAFENONE; QUINIDINE; RANOLAZINE; RPR 260243; RUFINAMIDE; TERFENADINE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTERY PERFUSION; ATRIOVENTRICULAR BLOCK; BRUGADA SYNDROME; CARDIOVASCULAR RISK; CHANNELOPATHY; CLINICAL PRACTICE; COMPUTER MODEL; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; ELECTROCARDIOGRAPHY; GENE MUTATION; HEART DEPOLARIZATION; HEART PAPILLARY MUSCLE; HEART PROARRHYTHMIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOLATED HEART; LONG QT SYNDROME; MUSCLE ACTION POTENTIAL; NONHUMAN; POSTMARKETING SURVEILLANCE; POTASSIUM CURRENT; PRACTICE GUIDELINE; PURKINJE FIBER; QT PROLONGATION; REPOLARIZATION; REVIEW; SHORT QT SYNDROME; TORSADE DES POINTES;

ANIMALS; ARRHYTHMIAS, CARDIAC; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; HEART CONDUCTION SYSTEM; HUMANS; LONG QT SYNDROME; MODELS, ANIMAL; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TORSADES DE POINTES;

ANIMALIA; CAVIA; ORYCTOLAGUS CUNICULUS;

EID: 77949953074     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11535230-000000000-00000     Document Type: Review

References (325)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119 (3): 480-486
2. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114 (10): e385-484
3. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321 (6): 406-412
4. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction: the SWORD Investigators (Survival With ORal d-Sotalol). Lancet 1996; 348 (9019): 7-12
5. Frey W. Weitere erfahrungen mit chinidin bei absoluter herzun-regelmabigkeit. Wien Med Wschr 1918; 55: 849-853
6. Selzer A, Wray HW. Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964; 30: 17-26
7. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999; 354 (9190): 1625-1633
8. Dessertenne F. Ventricular tachycardia with 2 variable opposing foci. Arch Mal Coeur Vaiss 1966; 59 (2): 263-272
9. Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. J Am Coll Cardiol 2004; 44 (1): 105-108
10. Farkas A, Qureshi A, Curtis MJ. Inadequate ischaemia-selectivity limits the antiarrhythmic efficacy of mibefradil during regional ischaemia and reperfusion in the rat isolated perfused heart. Br J Pharmacol 1999; 128 (1): 41-50
11. Watanabe Y. Effects of calcium and sodium concentrations on atrioventricular conduction: experimental study in rabbit hearts with clinical implications on heart block and slow calcium channel blocking agent usage. Am Heart J 1981; 102 (5): 883-891
12. Oros A, Beekman JD, Vos MA. The canine model with chronic, complete atrio-ventricular block. Pharmacol Ther 2008; 119 (2): 168-178
13. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15 (4): 475-495
14. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications: report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000; 47 (2): 219-233
15. Carlsson L. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes. Pharmacol Ther 2008; 119 (2): 160-167
16. Roden DM, Anderson ME. Proarrhythmia. Handb Exp Pharmacol 2006; (171): 73-97
17. Sarapa N, Britto MR. Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by non-adjuvant anticancer agents. Expert Opin Drug Saf 2008; 7 (3): 305-318
18. Thomsen MB, Matz J, Volders PG, et al. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther 2006; 112 (1): 150-170
19. International Conference on Harmonisation; guidance on S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals; availability. Notice. Fed Regist 2005; 70 (202): 61133-61134
20. International Conference on Harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Fed Regist 2005; 70 (202): 61134-61135
21. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1957; 54 (1): 59-68
22. Romano C, Gemme G, Pongiglione R. Rare cardiac arrhythmias of the pediatric age: I, repetitive paroxysmal tachycardia. Minerva Pediatr 1963; 15: 1155-1164
23. Ward OC. A new familial cardiac syndrome in children. J Ir Med Assoc 1964; 54: 103-106
24. Roden DM. Cellular basis of drug-induced torsades de pointes. Br J Pharmacol 2008; 154 (7): 1502-1507
25. Shah RR, Hondeghem LM. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2005; 2 (7): 758-772
26. Jackman WM, Friday KJ, Anderson JL, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31 (2): 115-172
27. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003; 24 (12): 619-625
28. Sipido KR, Varro A, Eisner D. Sodium calcium exchange as a target for antiarrhythmic therapy. Handb Exp Pharmacol 2006; (171): 73-97
29. Gallacher DJ, Van de Water A, van der Linde H, et al. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome. Cardiovasc Res 2007; 76 (2): 247-256
30. Ben Caref E, Boutjdir M, Himel HD, et al. Role of subendocardial Purkinje network in triggering torsade de pointes arrhythmia in experimental long QT syndrome. Europace 2008; 10 (10): 1218-1223
31. Nattel S, Quantz MA. Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. Cardiovasc Res 1988; 22 (11): 808-817
32. Tweedie D, O'Gara P, Harding SE, et al. The effect of alterations to action potential duration on beta-adrenoceptor-mediated aftercontractions in human and guinea-pig ventricular myocytes. J Mol Cell Cardiol 1997; 29 (5): 1457-1467
33. Volders PG, Kulcsar A, Vos MA, et al. Similarities between early and delayed afterdepolarizations induced by iso-proterenol in canine ventricular myocytes. Cardiovasc Res 1997; 34 (2): 348-359
34. Mazur A, Roden DM, Anderson ME. Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsade de pointes in rabbits. Circulation 1999; 100 (24): 2437-2442
35. Farkas AS, Makra P, Csik N, et al. The role of the Na+/Ca2+ exchanger, I(Na) and I(CaL) in the genesis of dofetilide-induced torsades de pointes in isolated, AV-blocked rabbit hearts. Br J Pharmacol 2009; 156 (6): 920-932
36. Hamlin RL, Kijtawornrat A. Use of the rabbit with a failing heart to test for torsadogenicity. Pharmacol Ther 2008; 119 (2): 179-185
37. Zygmunt AC, Goodrow RJ, Antzelevitch C. I(NaCa) contributes to electrical heterogeneity within the canine ventricle. Am J Physiol Heart Circ Physiol 2000; 278 (5): H1671-8
38. Milberg P, Pott C, Fink M, et al. Inhibition of the Na+/Ca2+ exchanger suppresses torsades de pointes in an intact heart model of long QT syndrome-2 and long QT syndrome-3. Heart Rhythm 2008; 5 (10): 1444-1452
39. Antzelevitch C. Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace 2007; 9 Suppl. 4: iv4-15
40. Milberg P, Reinsch N, Wasmer K, et al. Transmural dispersion of repolarization as a key factor of ar-rhythmogenicity in a novel intact heart model of LQT3. Cardiovasc Res 2005; 65 (2): 397-404
41. Antzelevitch C. Drug-induced spatial dispersion of repolarization. Cardiol J 2008; 15 (2): 100-121
42. Chen YJ, Hsieh MH, Chiou CW, et al. Electropharmacologic characteristics of ventricular proarrhythmia induced by ibutilide. J Cardiovasc Pharmacol 1999; 34 (2): 237-247
43. Haapalahti P, Viitasalo M, Perhonen M, et al. Electrocardiographic interventricular dispersion of repolariza-tion during autonomic adaptation in LQT1 subtype of long QT syndrome. Scand Cardiovasc J 2008; 42 (2): 130-136
44. Vos MA, Gorenek B, Verduyn SC, et al. Observations on the onset of torsade de pointes arrhythmias in the acquired long QT syndrome. Cardiovasc Res 2000; 48 (3): 421-429
45. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001; 103 (15): 2004-2013
46. Thomsen MB, Verduyn SC, Stengl M, et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 2004; 110 (16): 2453-2459
47. Hondeghem LM. Relative contributions of TRIaD and QT to proarrhythmia. J Cardiovasc Electrophysiol 2007; 18 (6): 655-657
48. Sicouri S, Glass A, Ferreiro M, et al. Transseptal dispersion of repolarization and its role in the development of torsade de pointes arrhythmias. J Cardiovasc Electrophysiol. Epub 2009 Nov 10
49. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983; 2 (5): 806-817
50. Noda T, Shimizu W, Satomi K, et al. Classification and mechanism of torsade de pointes initiation in patients with congenital long QT syndrome. Eur Heart J 2004; 25 (23): 2149-2154
51. El-Sherif N, Caref EB, Chinushi M, et al. Mechanism of arrhythmogenicity of the short-long cardiac sequence that precedes ventricular tachyarrhythmias in the long QT syndrome. J Am Coll Cardiol 1999; 33 (5): 1415-1423
52. Liu J, Laurita KR. The mechanism of pause-induced torsade de pointes in long QT syndrome. J Cardiovasc Electrophysiol 2005; 16 (9): 981-987
53. El-Sherif N, Turitto G. Torsade de pointes. Curr Opin Cardiol 2003; 18 (1): 6-13
54. El-Sherif N, Chinushi M, Caref EB, et al. Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long-QT syndrome: detailed analysis of ventricular tridimensional activation patterns. Circulation 1997; 96 (12): 4392-4399
55. Johnson JN, Tester DJ, Perry J, et al. Prevalence of earlyonset atrial fibrillation in congenital long QT syndrome. Heart Rhythm 2008; 5 (5): 704-709
56. Seslar SP, Shepard SM, Berul CI. "Atrial torsades de pointes" in the long QT syndrome. J Interv Card Elec-trophysiol 2009; 24 (2): 95-97
57. Kirchhof P, Eckardt L, Franz MR, et al. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol 2003; 14 (10): 1027-1033
58. Kirchhof P, Eckardt L, Monnig G, et al. A patient with "atrial torsades de pointes". J Cardiovasc Electrophysiol 2000; 11 (7): 806-811
59. Stansfeld PJ, Sutcliffe MJ, Mitcheson JS. Molecular mechanisms for drug interactions with hERG that cause long QT syndrome. Expert Opin Drug Metab Toxicol 2006; 2 (1): 81-94
60. Carlsson L. In vitro and in vivo models for testing arrhythmogenesis in drugs. J Intern Med 2006; 259 (1): 70-80
61. Gintant GA. Preclinical torsades-de-pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Pharmacol Ther 2008; 119 (2): 199-209
62. Lawrence CL, Bridgland-Taylor MH, Pollard CE, et al. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of torsades de pointes. Br J Pharmacol 2006; 149 (7): 845-860
63. Lawrence CL, Pollard CE, Hammond TG, et al. In vitro models of proarrhythmia. Br J Pharmacol 2008; 154 (7): 1516-1522
64. Lewis BH, Antman EM, Graboys TB. Detailed analysis of 24 hour ambulatory electrocardiographic recordings during ventricular fibrillation or torsade de pointes. J Am Coll Cardiol 1983; 2 (3): 426-436
65. Yan GX, Wu Y, Liu T, et al. Phase 2 early after depolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 2001; 103 (23): 2851-2856
66. Hlaing T, DiMino T, Kowey PR, et al. ECG repolarization waves: their genesis and clinical implications. Ann Noninvasive Electrocardiol 2005; 10 (2): 211-223
67. Armoundas AA, Nanke T, Cohen RJ. Images in cardiovascular medicine: T-wave alternans preceding torsade de pointes ventricular tachycardia. Circulation 2000; 101 (21): 2550
68. Tomcsanyi J, Somloi M, Fresz T, et al. T-wave alternans and torsade de pointes ventricular tachycardia in a patient with intracerebral hemorrhage. Orv Hetil 2003; 144 (42): 2077-2079
69. Wegener FT, Ehrlich JR, Hohnloser SH. Amiodarone-associated macroscopic T-wave alternans and torsade de pointes unmasking the inherited long QT syndrome. Europace 2008; 10 (1): 112-113
70. Cutler MJ, Rosenbaum DS. Risk stratification for sudden cardiac death: is there a clinical role for T wave alternans? Heart Rhythm 2009; 6 (8 Suppl.): S56-61
71. Garcia Ede V. T-wave alternans: reviewing the clinical performance, understanding limitations, characterizing methodologies. Ann Noninvasive Electrocardiol 2008; 13 (4): 401-420
72. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998; 98 (18): 1928-1936
73. Antzelevitch C, Oliva A. Amplification of spatial dispersion of repolarization underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT, short QT and Brugada syndromes. J Intern Med 2006; 259 (1): 48-58
74. Wu L, Guo D, Li H, et al. Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm 2008; 5 (12): 1726-1734
75. Yamaguchi M, Shimizu M, Ino H, et al. T wave peakto-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (Lond) 2003; 105 (6): 671-676
76. Zhang H, Kharche S, Holden AV, et al. Repolarisation and vulnerability to re-entry in the human heart with short QT syndrome arising from KCNQ1 mutation: a simulation study. Prog Biophys Mol Biol 2008; 96 (1-3): 112-131
77. Letsas KP, Weber R, Astheimer K, et al. Tpeak-Tend interval and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility in subjects with Brugada ECG pheno-type. Europace 2010; 12 (2): 271-274
78. Nemec J, Hejlik JB, Shen WK, et al. Catecholamine-induced T-wave lability in congenital long QT syndrome: a novel phenomenon associated with syncope and cardiac arrest. Mayo Clin Proc 2003; 78 (1): 40-50
79. Carlsson L, Andersson B, Linhardt G, et al. Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo. J Cardiovasc Pharmacol 2009; 54 (1): 82-89
80. Lengyel C, Varro A, Tabori K, et al. Combined pharma-cological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes. Br J Pharmacol 2007; 151 (7): 941-951
81. Hinterseer M, Thomsen MB, Beckmann BM, et al. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study. Eur Heart J 2008; 29 (2): 185-190
82. Hinterseer M, Beckmann BM, Thomsen MB, et al. Relation of increased short-term variability of QT interval to congenital long-QT syndrome. Am J Cardiol 2009; 103 (9): 1244-1248
83. van der Linde H, Van de Water A, Loots W, et al. A new method to calculate the beat-to-beat instability of QT duration in drug-induced long QT in anesthetized dogs. J Pharmacol Toxicol Methods 2005; 52 (1): 168-177
84. Brennan M, Palaniswami M, Kamen P. Do existing measures of Poincare plot geometry reflect nonlinear features of heart rate variability? IEEE Trans Biomed Eng 2001; 48 (11): 1342-1347
85. Perkiomaki JS, Zareba W, Nomura A, et al. Repolarization dynamics in patients with long QT syndrome. J Cardiovasc Electrophysiol 2002; 13 (7): 651-656
86. Vincze D, Farkas AS, Rudas L, et al. Relevance of anaesthesia for dofetilide-induced torsades de pointes in alpha1-adrenoceptor-stimulated rabbits. Br J Pharmacol 2008; 153 (1): 75-89
87. Copie X, Le Heuzey JY, Iliou MC, et al. Correlation between time-domain measures of heart rate variability and scatterplots in postinfarction patients. Pacing Clin Electrophysiol 1996; 19 (3): 342-347
88. Schoenwald RD, Isaacs VE. QT corrected for heart rate: a new approach and its application. Arch Int Pharmacodyn Ther 1974; 211 (1): 34-48
89. Berger RD, Kasper EK, Baughman KL, et al. Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyo-pathy. Circulation 1997; 96 (5): 1557-1565
90. Bilchick K, Viitasalo M, Oikarinen L, et al. Temporal repolarization lability differences among genotyped patients with the long QT syndrome. Am J Cardiol 2004; 94 (10): 1312-1316
91. Champeroux P, Martel E, Fowler JS, et al. Calculation of QT shift in non clinical safety pharmacology studies. J Pharmacol Toxicol Methods 2009; 59 (2): 73-85
92. Fossa AA. Assessing QT prolongation in conscious dogs: validation of a beat-to-beat method. Pharmacol Ther 2008; 119 (2): 133-140
93. Krahn AD, Yee R, Chauhan V, et al. Beta blockers normalize QT hysteresis in long QT syndrome. Am Heart J 2002; 143 (3): 528-534
94. Van Deuren B, Van Ammel K, Somers Y, et al. The fentanyl/etomidate- anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research. J Pharmacol Toxicol Methods 2009; 60 (1): 11-23
95. Bertinieri G, Di Rienzo M, Cavallazzi A, et al. Evaluation of baroreceptor reflex by blood pressure monitoring in unanesthetized cats. Am J Physiol 1988; 254 (2 Pt 2): H377-83
96. Schwartz PJ, Vanoli E, Crotti L, et al. Neural control of heart rate is an arrhythmia risk modifier in long QT syndrome. J Am Coll Cardiol 2008; 51 (9): 920-929
97. Billman GE, Schwartz PJ, Stone HL. Baroreceptor reflex control of heart rate: a predictor of sudden cardiac death. Circulation 1982; 66 (4): 874-880
98. Nattel S, Comtois P. Teasing out circadian variability in heart rate turbulence: a new approach to detecting bior-hythms underlying cardiac function. Heart Rhythm 2007; 4 (3): 301-303
99. Guzik P, Schmidt G. A phenomenon of heart-rate turbulence, its evaluation, and prognostic value. Card Electro-physiol Rev 2002; 6 (3): 256-261
100. Grimm W, Schmidt G, Maisch B, et al. Prognostic significance of heart rate turbulence following ventricular premature beats in patients with idiopathic dilated cardi-omyopathy. J Cardiovasc Electrophysiol 2003; 14 (8): 819-824
101. Verrier RL, Antzelevitch C. Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol 2004; 19 (1): 2-11
102. Lombardi F. Clinical implications of present physiological understanding of HRV components. Card Electrophysiol Rev 2002; 6 (3): 245-249
103. Pierre B, Babuty D, Poret P, et al. Abnormal nocturnal heart rate variability and QT dynamics in patients with Brugada syndrome. Pacing Clin Electrophysiol 2007; 30 Suppl. 1: S188-91
104. Perkiomaki JS, Zareba W, Couderc JP, et al. Heart rate variability in patients with congenital long QT syndrome. Ann Noninvasive Electrocardiol 2001; 6 (4): 298-304
105. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Car-diol 2000; 35 (3): 778-786
106. Michael G, Kane KA, Coker SJ. Adrenaline reveals the torsadogenic effect of combined blockade of potassium channels in anaesthetized guinea pigs. Br J Pharmacol 2008; 154 (7): 1414-1426
107. Ring CL, Idriss SF, Neu WK. Variability of action potential duration in pharmacologically induced long QT syndrome type 1. Conf Proc IEEE Eng Med Biol Soc 2009; 1: 4520-4522
108. Seebohm G, Pusch M, Chen J, et al. Pharmacological activation of normal and arrhythmia-associated mutant KCNQ1 potassium channels. Circ Res 2003; 93 (10): 941-947
109. Nissen JD, Diness JG, Diness TG, et al. Pharmacologically induced long QT type 2 can be rescued by activation of IKs with benzodiazepine R-L3 in isolated guinea pig cardiomyocytes. J Cardiovasc Pharmacol 2009; 54 (2): 169-177
110. Farkas AS, Acsai K, Toth A, et al. Importance of extracardiac alpha1-adrenoceptor stimulation in assisting dofetilide to induce torsade de pointes in rabbit hearts. Eur J Pharmacol 2006; 537 (1-3): 118-125
111. Farkas A, Dempster J, Coker SJ. Importance of vagally mediated bradycardia for the induction of torsade de pointes in an in vivo model. Br J Pharmacol 2008; 154 (5): 958-970
112. Yamauchi S, Yamaki M, Watanabe T, et al. Restitution properties and occurrence of ventricular arrhythmia in LQT2 type of long QT syndrome. J Cardiovasc Electro-physiol 2002; 13 (9): 910-914
113. Hansen RS, Diness TG, Christ T, et al. Activation of human ether-a-go-go-related gene potassium channels by the di-phenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Mol Pharmacol 2006; 69 (1): 266-277
114. Hansen RS, Diness TG, Christ T, et al. Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)-N'-(3'-trifluoromethylphenyl)urea]. Mol Pharmacol 2006; 70 (4): 1319-1329
115. Grunnet M, Hansen RS, Olesen SP. hERG1 channel activators: a new anti-arrhythmic principle. Prog Biophys Mol Biol 2008; 98 (2-3): 347-362
116. Yap YG, Behr ER, Camm AJ. Drug-induced Brugada syndrome. Europace 2009; 11 (8): 989-994
117. Veltmann C, Wolpert C, Sacher F, et al. Response to intravenous ajmaline: a retrospective analysis of 677 aj-maline challenges. Europace 2009; 11 (10): 1345-1352
118. Stokoe KS, Balasubramaniam R, Goddard CA, et al. Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/-murine hearts modelling the Bru-gada syndrome. J Physiol 2007; 581 (Pt 1): 255-275
119. Michael G, Dempster J, Kane KA, et al. Potentiation of E-4031-induced torsade de pointes by HMR1556 or ATX-II is not predicted by action potential short-term variability or triangulation. Br J Pharmacol 2007; 152 (8): 1215-1227
120. Milberg P, Reinsch N, Osada N, et al. Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early after-depolarizations in an intact heart model of LQT3. Basic Res Cardiol 2005; 100 (4): 365-371
121. Patel C, Antzelevitch C. Pharmacological approach to the treatment of long and short QT syndromes. Pharmacol Ther 2008; 118 (1): 138-151
122. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115 (4): 442-449
123. Sicouri S, Timothy KW, Zygmunt AC, et al. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm 2007; 4 (5): 638-647
124. Cheng HC, Incardona J. Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chro-manol 293B in isolated rabbit and guinea pig hearts. J Pharmacol Toxicol Methods 2009; 60 (2): 174-184
125. Chaudhry GM, Haffajee CI. Antiarrhythmic agents and proarrhythmia. Crit Care Med 2000; 28 (10 Suppl.): N158-64
126. Remme CA, Verkerk AO, Nuyens D, et al. Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD. Circulation 2006; 114 (24): 2584-2594
127. Remme CA, Wilde AA, Bezzina CR. Cardiac sodium channel overlap syndromes: different faces of SCN5A mutations. Trends Cardiovasc Med 2008; 18 (3): 78-87
128. Postema PG, Van den Berg M, Van Tintelen JP, et al. Founder mutations in the Netherlands: SCN5a 1795insD, the first described arrhythmia overlap syndrome and one of the largest and best characterised families worldwide. Neth Heart J 2009; 17 (11): 422-428
129. Algra A, Tijssen JG, Roelandt JR, et al. QT interval variables from 24 hour electrocardiography and the two year risk of sudden death. Br Heart J 1993; 70 (1): 43-48
130. Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? Cardiology 2000; 94 (2): 99-102
131. Bellocq C, van Ginneken AC, Bezzina CR, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004; 109 (20): 2394-2397
132. Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109 (1): 30-35
133. Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005; 96 (7): 800-807
134. Shah RR. Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol 2010; 159 (1): 58-69
135. Kang J, Chen XL, Wang H, et al. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel. Mol Pharmacol 2005; 67 (3): 827-836
136. Zhou J, Augelli-Szafran CE, Bradley JA, et al. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol 2005; 68 (3): 876-884
137. Pugsley MK, Hancox JC, Curtis MJ. Perception of validity of clinical and preclinical methods for assessment of tor-sades de pointes liability. Pharmacol Ther 2008; 119 (2): 115-117
138. Abi-Gerges N, Small BG, Lawrence CL, et al. Evidence for gender differences in electrophysiological properties of canine Purkinje fibres. Br J Pharmacol 2004; 142 (8): 1255-1264
139. Wang D, Patel C, Cui C, et al. Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation. Pharmacol Ther 2008; 119 (2): 141-151
140. Tomaselli GF, Rose J. Molecular aspects of arrhythmias associated with cardiomyopathies. Curr Opin Cardiol 2000; 15 (3): 202-208
141. Vos MA, van Opstal JM, Leunissen JD, et al. Electro-physiologic parameters and predisposing factors in the generation of drug-induced torsade de pointes arrhythmias. Pharmacol Ther 2001; 92 (2-3): 109-122
142. Dhein S, Perlitz F, Mohr FW. An in vitro model for assessment of drug-induced torsade de pointes arrhythmia: effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia. Naunyn Schmiedebergs Arch Pharmacol 2008; 378 (6): 631-644
143. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiar-rhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 1990; 16 (2): 276-285
144. Vos MA, Verduyn SC, Gorgels AP, et al. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation 1995; 91 (3): 864-872
145. Toyoshima S, Kanno A, Kitayama T, et al. QT PRO-DACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J Pharmacol Sci 2005; 99 (5): 459-471
146. Ando K, Hombo T, Kanno A, et al. QT PRODACT: in vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. J Pharmacol Sci 2005; 99 (5): 487-500
147. Lindgren S, Bass AS, Briscoe R, et al. Benchmarking safety pharmacology regulatory packages and best practice. J Pharmacol Toxicol Methods 2008; 58 (2): 99-109
148. Bass AS, Darpo B, Breidenbach A, et al. International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes. Br J Pharmacol 2008; 154 (7): 1491-1501
149. Aronov AM. Predictive in silico modeling for hERG channel blockers. Drug Discov Today 2005; 10 (2): 149-155
150. Kleber AG, Rudy Y. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev 2004; 84 (2): 431-488
151. Arrigoni C, Crivori P. Assessment of QT liabilities in drug development. Cell Biol Toxicol 2007; 23 (1): 1-13
152. Bender A, Scheiber J, Glick M, et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. Chem Med Chem 2007; 2 (6): 861-873
153. Grandi E, Pasqualini FS, Pes C, et al. Theoretical investigation of action potential duration dependence on extracellular Ca2+ in human cardiomyocytes. J Mol Cell Cardiol 2009; 46 (3): 332-342
154. Vecchietti S, Grandi E, Severi S, et al. In silico assessment of Y1795C and Y1795H SCN5A mutations: implication for inherited arrhythmogenic syndromes. Am J Physiol Heart Circ Physiol 2007; 292 (1): H56-65
155. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 1998; 21 (5): 1029-1034
156. Hancox JC, McPate MJ, El Harchi A, et al. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 2008; 119 (2): 118-132
157. Nattel S, Duker G, Carlsson L. Model systems for the discovery and development of antiarrhythmic drugs. Prog Biophys Mol Biol 2008; 98 (2-3): 328-339
158. Kirsch GE, Trepakova ES, Brimecombe JC, et al. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 2004; 50 (2): 93-101
159. Yao JA, Du X, Lu D, et al. Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature. J Pharmacol Toxicol Methods 2005; 52 (1): 146-153
160. Sanguinetti MC, Jiang C, Curran ME, et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81 (2): 299-307
161. Yang T, Snyders DJ, Roden DM. Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ Res 1997; 80 (6): 782-789
162. Stork D, Timin EN, Berjukow S, et al. State dependent dissociation of HERG channel inhibitors. Br J Pharmacol 2007; 151 (8): 1368-1376
163. Yang T, Snyders D, Roden DM. Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001; 38 (5): 737-744
164. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110 (8): 904-910
165. Schram G, Zhang L, Derakhchan K, et al. Ranolazine: ionchannel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 2004; 142 (8): 1300-1308
166. Cavero I, Mestre M, Guillon JM, et al. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 2000; 1 (5): 947-973
167. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58 (1): 32-45
168. Ficker E, Dennis AT, Wang L, et al. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 2003; 92 (12): e87-100
169. Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97 (5): 1514-1516
170. Wang L, Wible BA, Wan X, et al. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J Pharmacol Exp Ther 2007; 320 (2): 525-534
171. Wible BA, Hawryluk P, Ficker E, et al. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 2005; 52 (1): 136-145
172. Rezazadeh S, Hesketh JC, Fedida D. Rb+ flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb+ efflux assay. J Biomol Screen 2004; 9 (7): 588-597
173. Chaudhary KW, O'Neal JM, Mo ZL, et al. Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade. Assay Drug Dev Technol 2006; 4 (1): 73-82
174. Titus SA, Beacham D, Shahane SA, et al. A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Anal Biochem 2009; 394 (1): 30-38
175. Meyer T, Sartipy P, Blind F, et al. New cell models and assays in cardiac safety profiling. Expert Opin Drug Metab Toxicol 2007; 3 (4): 507-517
176. Lu HR, Vlaminckx E, Hermans AN, et al. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B guidelines. Br J Pharmacol 2008; 154 (7): 1427-1438
177. Hosaka Y, Iwata M, Kamiya N, et al. Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant. Channels (Austin) 2007; 1 (3): 198-208
178. Jo SH, Hong HK, Chong SH, et al. Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652. Eur J Pharmacol 2008; 592 (1-3): 19-25
179. Kamiya K, Niwa R, Morishima M, et al. Molecular determinants of hERG channel block by terfenadine and cisapride. J Pharmacol Sci 2008; 108 (3): 301-307
180. Shah RR. Drug-induced QT interval prolongation: regulatory guidance and perspectives on hERG channel studies. Novartis Found Symp 2005; 266: 251-80; discussion 80-85
181. Witchel HJ. The hERG potassium channel as a therapeutic target. Expert Opin Ther Targets 2007; 11 (3): 321-336
182. Martin RL, McDermott JS, Salmen HJ, et al. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol 2004; 43 (3): 369-379
183. Limberis JT, McDermott JS, Salmen HJ, et al. The effects of plasma proteins on delayed repolarization in vitro with cisapride, risperidone, and D,L-sotalol. J Pharmacol Toxicol Methods 2007; 56 (1): 11-17
184. Hanson LA, Bass AS, Gintant G, et al. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods 2006; 54 (2): 116-129
185. Lu HR, Vlaminckx E, Van de Water A, et al. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 2006; 553 (1-3): 229-239
186. Hayashi S, Kii Y, Tabo M, et al. QT PRODACT: a multisite study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles. J Pharmacol Sci 2005; 99 (5): 423-437
187. Kii Y, Hayashi S, Tabo M, et al. QT PRODACT: evaluation of the potential of compounds to cause QT interval prolongation by action potential assays using guinea-pig papillary muscles. J Pharmacol Sci 2005; 99 (5): 449-457
188. Yan GX, Shimizu W, Antzelevitch C. Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. Circulation 1998; 98 (18): 1921-1927
189. Poelzing S. Are electrophysiologically distinct M-cells a characteristic of the wedge preparation? Heart Rhythm 2009; 6 (7): 1035-1037
190. Voss F, Opthof T, Marker J, et al. There is no transmural heterogeneity in an index of action potential duration in the canine left ventricle. Heart Rhythm 2009; 6 (7): 1028-1034
191. Opthof T, Coronel R, Wilms-Schopman FJ, et al. Dispersion of repolarization in canine ventricle and the electro-cardiographic T wave: Type interval does not reflect transmural dispersion. Heart Rhythm 2007; 4 (3): 341-348
192. Di Diego JM, Belardinelli L, Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 2003; 108 (8): 1027-1033
193. Wu L, Rajamani S, Li H, et al. Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart. Am J Physiol Heart Circ Physiol 2009; 297 (3): H1048-57
194. Extramiana F, Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmo-genesis in a canine ventricular-wedge model of short-QT syndrome. Circulation 2004; 110 (24): 3661-3666
195. Patel C, Antzelevitch C. Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm 2008; 5 (4): 585-590
196. Calloe K, Cordeiro JM, Di Diego JM, et al. A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. Cardiovasc Res 2009; 81 (4): 686-694
197. Morita H, Zipes DP, Fukushima-Kusano K, et al. Repolarization heterogeneity in the right ventricular outflow tract: correlation with ventricular arrhythmias in Brugada patients and in an in vitro canine Brugada model. Heart Rhythm 2008; 5 (5): 725-733
198. Joshi A, Dimino T, Vohra Y, et al. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models. J Electrocardiol 2004; 37 Suppl.: 7-14
199. Liu T, Brown BS, Wu Y, et al. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 2006; 3 (8): 948-956
200. Chen X, Cordes JS, Bradley JA, et al. Use of arterially perfused rabbit ventricular wedge in predicting arrhy-thmogenic potentials of drugs. J Pharmacol Toxicol Methods 2006; 54 (3): 261-272
201. Valentin JP, Hoffmann P, De Clerck F, et al. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J Pharmacol Toxicol Methods 2004; 49 (3): 171-181
202. Hondeghem LM, Lu HR, van Rossem K, et al. Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol 2003; 14 (3): 287-294
203. Guo L, Dong Z, Guthrie H. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. J Pharmacol Toxicol Methods 2009; 60 (2): 833-843
204. Hondeghem LM, Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J Cardiovasc Pharmacol 2003; 41 (1): 14-24
205. Dumotier BM, Deurinck M, Yang Y, et al. Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: a database review and analysis. Pharmacol Ther 2008; 119 (2): 152-159
206. Hondeghem LM. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct. Eur J Pharmacol 2008; 584 (1): 1-9
207. Zabel M, Hohnloser SH, Behrens S, et al. Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model. J Cardiovasc Electro-physiol 1997; 8 (10): 1148-1158
208. Johna R, Mertens H, Haverkamp W, et al. Clofilium in the isolated perfused rabbit heart: a new model to study proarrhythmia induced by class III antiarrhythmic drugs. Basic Res Cardiol 1998; 93 (2): 127-135
209. Milberg P, Hilker E, Ramtin S, et al. Proarrhythmia as a class effect of quinolones: increased dispersion of re-polarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol 2007; 18 (6): 647-654
210. Lu HR, Vlaminckx E, Van de Water A, et al. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 2007; 577 (1-3): 222-232
211. Gray RA, Jalife J, Panfilov A, et al. Nonstationary vortexlike reentrant activity as a mechanism of polymorphic ventricular tachycardia in the isolated rabbit heart. Circulation 1995; 91 (9): 2454-2469
212. Shimizu W, Antzelevitch C. Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation 2000; 102 (6): 706-712
213. Farkas A, Lepran I, Papp JG. Comparison of the antiarrhythmic and the proarrhythmic effect of almokalant in anaesthetised rabbits. Eur J Pharmacol 1998; 346 (2-3): 245-253
214. Farkas A, Coker SJ. Limited induction of torsade de pointes by terikalant and erythromycin in an in vivo model. Eur J Pharmacol 2002; 449 (1-2): 143-153
215. Farkas A, Coker SJ. Prevention of clofilium-induced torsade de pointes by prostaglandin E2 does not involve ATP-dependent K+ channels. Eur J Pharmacol 2003; 472 (3): 189-196
216. Fedida D, Braun AP, Giles WR. Alpha1-adrenoceptors reduce background K+ current in rabbit ventricular myocytes. J Physiol 1991; 441: 673-684
217. Fedida D, Braun AP, Giles WR. Alpha1-adrenoceptors in myocardium: functional aspects and transmembrane signaling mechanisms. Physiol Rev 1993; 73 (2): 469-487
218. Fedida D, Shimoni Y, Giles WR. Alpha-adrenergic modulation of the transient outward current in rabbit atrial myocytes. J Physiol 1990; 423: 257-277
219. Terzic A, Puceat M, Vassort G, et al. Cardiac alpha1-adrenoceptors: an overview. Pharmacol Rev 1993; 45 (2): 147-175
220. Steinberg SF, Kaplan LM, Inouye T, et al. Alpha-1 adrenergic stimulation of 1,4,5-inositol trisphosphate formation in ventricular myocytes. J Pharmacol Exp Ther 1989; 250 (3): 1141-1148
221. Carlsson L, Drews L, Duker G. Rhythm anomalies related to delayed repolarization in vivo: influence of sarcolemmal Ca++ entry and intracellular Ca++ overload. J Pharmacol Exp Ther 1996; 279 (1): 231-239
222. Wang WQ, Robertson C, Dhalla AK, et al. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl] -1-piperazine) (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther 2008; 325 (3): 875-881
223. Farkas A, Batey AJ, Coker SJ. How to measure electrocardiographic QT interval in the anaesthetized rabbit. J Pharmacol Toxicol Methods 2004; 50 (3): 175-185
224. Farkas A, Lepran I, Papp JG. Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and al-mokalant in the anesthetized rabbit model of torsade de pointes. J Cardiovasc Pharmacol 2002; 39 (2): 287-297
225. Lu HR, Remeysen P, De Clerck F. Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation. J Cardiovasc Pharmacol 2000; 36 (6): 728-736
226. Provan G, Stanton A, Sutton A, et al. Development of a surgical approach for telemetering guinea pigs as a model for screening QT interval effects. J Pharmacol Toxicol Methods 2005; 52 (2): 223-228
227. Chaves AA, Keller WJ, O'Sullivan S, et al. Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation. J Pharmacol Toxicol Methods 2006; 54 (2): 150-158
228. Chaves AA, Zingaro GJ, Yordy MA, et al. A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. J Pharmacol Toxicol Methods 2007; 56 (2): 103-114
229. van der Linde HJ, Van Deuren B, Teisman A, et al. The effect of changes in core body temperature on the QT interval in beagle dogs: a previously ignored phenomenon, with a method for correction. Br J Pharmacol 2008; 154 (7): 1474-1481
230. Han W, Chartier D, Li D, et al. Ionic remodeling of cardiac Purkinje cells by congestive heart failure. Circulation 2001; 104 (17): 2095-2100
231. Nabauer M, Kaab S. Potassium channel down-regulation in heart failure. Cardiovasc Res 1998; 37 (2): 324-334
232. Tsuji Y, Zicha S, Qi XY, et al. Potassium channel subunit remodeling in rabbits exposed to long-term bradycardia or tachycardia: discrete arrhythmogenic consequences related to differential delayed-rectifier changes. Circulation 2006; 113 (3): 345-355
233. Li X, Huang CX, Jiang H, et al. The beta-adrenergic blocker carvedilol restores L-type calcium current in a myocardial infarction model of rabbit. Chin Med J (Engl) 2005; 118 (5): 377-382
234. Varro A, Papp JG. Low penetrance, subclinical congenital LQTS: concealed LQTS or silent LQTS? Cardiovasc Res 2006; 70 (3): 404-406
235. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca(2+) release causes myocyte depolarization: underlying mechanism and threshold for triggered action potentials. Circ Res 2000; 87 (9): 774-780
236. Volders PG, Sipido KR, Vos MA, et al. Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circulation 1998; 98 (11): 1136-1147
237. Volders PG, Sipido KR, Vos MA, et al. Downregulation of delayed rectifier K(+) currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation 1999; 100 (24): 2455-2461
238. Tsuji Y, Opthof T, Yasui K, et al. Ionic mechanisms of acquired QT prolongation and torsades de pointes in rabbits with chronic complete atrioventricular block. Circulation 2002; 106 (15): 2012-2018
239. Vos MA, de Groot SH, Verduyn SC, et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation 1998; 98 (11): 1125-1135
240. de Groot SH, Schoenmakers M, Molenschot MM, et al. Contractile adaptations preserving cardiac output predispose the hypertrophied canine heart to delayed afterdepolarization-dependent ventricular arrhythmias. Circulation 2000; 102 (17): 2145-2151
241. Donker DW, Volders PG, Arts T, et al. End-diastolic myofiber stress and ejection strain increase with ventricular volume overload: serial in-vivo analyses in dogs with complete atrioventricular block. Basic Res Cardiol 2005; 100 (4): 372-382
242. Schoenmakers M, Ramakers C, van Opstal JM, et al. Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog. Cardiovasc Res 2003; 59 (2): 351-359
243. Sipido KR, Volders PG, de Groot SH, et al. Enhanced Ca(2+) release and Na/Ca exchange activity in hyper-trophied canine ventricular myocytes: potential link between contractile adaptation and arrhythmogenesis. Circulation 2000; 102 (17): 2137-2144
244. Nattel S, Wang ZG, Matthews C. Direct electrophysiological actions of pentobarbital at concentrations achieved during general anesthesia. Am J Physiol 1990; 259 (6 Pt 2): H1743-51
245. Stadnicka A, Bosnjak ZJ, Kampine JP, et al. Modulation of cardiac inward rectifier K(+)current by halothane and isoflurane. Anesth Analg 2000; 90 (4): 824-833
246. Bachmann A, Mueller S, Kopp K, et al. Inhibition of cardiac potassium currents by pentobarbital. Naunyn Schmiede-bergs Arch Pharmacol 2002; 365 (1): 29-37
247. Qi XY, Yeh YH, Chartier D, et al. The calcium/ calmodulin/kinase system and arrhythmogenic after-depolarizations in bradycardia-related acquired long QT syndrome. Circulation Arrhythmia Electrophysiol 2009; 2 (3): 295-304
248. Satoh Y, Sugiyama A, Takahara A, et al. A novel monkey proarrhythmia model that can predict the drug-induced torsades de pointes in clinical practice [abstract]. J Pharmacol Sci 2006; 100 Suppl. I: 223
249. Sugiyama A. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol 2008; 154 (7): 1528-1537
250. Hashimoto K. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative. Pharmacol Ther 2008; 119 (2): 195-198
251. Kijtawornrat A, Nishijima Y, Roche BM, et al. Use of a failing rabbit heart as a model to predict torsadogenicity. Toxicol Sci 2006; 93 (1): 205-212
252. Schwartz PJ, Malliani A. Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. Am Heart J 1975; 89 (1): 45-50
253. Surawicz B, Fisch C. Cardiac alternans: diverse mechanisms and clinical manifestations. J Am Coll Cardiol 1992; 20 (2): 483-499
254. Zareba W, Moss AJ, le Cessie S, et al. T wave alternans in idiopathic long QT syndrome. J Am Coll Cardiol 1994; 23 (7): 1541-1546
255. Houltz B, Darpo B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol 1998; 21 (5): 1044-1057
256. Brockmeier K, Aslan I, Hilbel T, et al. T-wave alternans in LQTS: repolarization-rate dynamics from digital 12-lead Holter data. J Electrocardiol 2001; 34 Suppl.: 93-96
257. Shimizu W, Antzelevitch C. Cellular and ionic basis for T-wave alternans under long-QT conditions. Circulation 1999; 99 (11): 1499-1507
258. Schmitt J, Baumann S, Klingenheben T, et al. Assessment of microvolt T-wave alternans in high-risk patients with the congenital long-QT syndrome. Ann Noninvasive Electrocardiol 2009; 14 (4): 340-345
259. Berger RD. QT variability. J Electrocardiol 2003; 36 Suppl.: 83-87
260. Mine T, Shimizu H, Hiromoto K, et al. Beat-to-beat QT interval variability is primarily affected by the autonomic nervous system. Ann Noninvasive Electrocardiol 2008; 13 (3): 228-233
261. Iwasa A, Hwa M, Hassankhani A, et al. Abnormal heart rate turbulence predicts the initiation of ventricular arrhythmias. Pacing Clin Electrophysiol 2005; 28 (11): 1189-1197
262. Watanabe MA. Heart rate turbulence slope reduction in imminent ventricular tachyarrhythmia and its implications. J Cardiovasc Electrophysiol 2006; 17 (7): 735-740
263. Bass AS, Darpo B, Valentin JP, et al. Moving towards better predictors of drug-induced torsades de pointes. Br J Pharmacol 2008; 154 (7): 1550-1553
264. Bauman JL, Bauernfeind RA, Hoff JV, et al. Torsade de pointes due to quinidine: observations in 31 patients. Am Heart J 1984; 107 (3): 425-430
265. Chan AS, Isbister GK, Kirkpatrick CM, et al. Assessing risk of a prolonged QT interval: a survey of emergency physicians. Int J Emerg Med 2008; 1 (1): 35-41
266. Batchvarov VN, Ghuran A, Smetana P, et al. QT-RR relationship in healthy subjects exhibits substantial inter-subject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 2002; 282 (6): H2356-63
267. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 2001; 24 (5): 323-351
268. Hodges M. Rate correction of the QT interval. Card Electrophysiol Rev 1997; 1 (3): 360-363
269. Smetana P, Batchvarov V, Hnatkova K, et al. Circadian rhythm of the corrected QT interval: impact of different heart rate correction models. Pacing Clin Electrophysiol 2003 Jan; 26 (1 Pt 2): 383-386
270. Camm AJ. Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art. Heart Rhythm 2005; 2 (2 Suppl.): S23-9
271. Letsas KP, Efremidis M, Kounas SP, et al. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors. Clin Res Cardiol 2009; 98 (4): 208-212
272. Shah RR. If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed? Pharmacol Ther 2008; 119 (2): 215-221
273. Jonker DM, Kenna LA, Leishman D, et al. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clin Pharmacol Ther 2005; 77 (6): 572-582
274. Piccini JP, Whellan DJ, Berridge BR, et al. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Am Heart J 2009; 158 (3): 317-326
275. Heist EK, Ruskin JN. Drug-induced proarrhythmia and use of QTc-prolonging agents: clues for clinicians. Heart Rhythm 2005; 2 (2 Suppl.): S1-8
276. Makita N, Horie M, Nakamura T, et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 2002; 106 (10): 1269-1274
277. Itoh H, Sakaguchi T, Ding WG, et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ Arrhythm Electrophysiol 2009; 2 (5): 511-523
278. Astrom-Lilja C, Odeberg JM, Ekman E, et al. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf 2008; 17 (6): 587-592
279. Peters RW, Gold MR. The influence of gender on arrhythmias. Cardiol Rev 2004; 12 (2): 97-105
280. Schrickel JW, Schwab JO, Yang A, et al. "Torsade de pointes" in patients with structural heart disease and atrial fibrillation treated with amiodarone, beta-blockers, and digitalis. Pacing Clin Electrophysiol 2006; 29 (4): 363-366
281. DiCoriA,GemignaniC,BiniR,et al. "Torsadedepointes" in a patient with variant angina. Ital Heart J 2004; 5 (7): 554-558
282. Kozhevnikov DO, Yamamoto K, Robotis D, et al. Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: tridimensional mapping of activation and recovery patterns. Circulation 2002; 105 (9): 1128-1134
283. Pedersen HS, Elming H, Seibaek M, et al. Risk factors and predictors of torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving dofetilide. Am J Cardiol 2007; 100 (5): 876-880
284. Elming H, Brendorp B, Kober L, et al. QTc interval in the assessment of cardiac risk. Card Electrophysiol Rev 2002; 6 (3): 289-294
285. Samuelov-Kinori L, Kinori M, Kogan Y, et al. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes? J Electro-cardiol 2009 Jul-Aug; 42 (4): 353-357
286. Choy AM, Darbar D, Dell'Orto S, et al. Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol 1999; 34 (2): 396-401
287. Koster RW, Wellens HJ. Quinidine-induced ventricular flutter and fibrillation without digitalis therapy. Am J Cardiol 1976; 38 (4): 519-523
288. Badorff C, Zeiher AM, Hohnloser SH. Torsade de pointes tachycardia as a rare manifestation of acute enteroviral myocarditis. Heart 2001; 86 (5): 489-490
289. Sani IM, Solomon DS, Imhogene OA, et al. QT dispersion in adult hypertensives. J Natl Med Assoc 2006; 98 (4): 631-636
290. McLean A, Sceats G. Torsade de pointes associated with thyrotoxicosis. Intern Med J 2003; 33 (4): 207-208
291. Kearney P, Reardon M, O'Hare J. Primary hyperparathy-roidism presenting as torsades de pointes. Br Heart J 1993; 70 (5): 473
292. Shimizu K, Miura Y, Meguro Y, et al. QT prolongation with torsade de pointes in pheochromocytoma. Am Heart J 1992; 124 (1): 235-239
293. Sade E, Oto A, Oner Z, et al. Adrenal adenoma presenting with torsade de pointes: a case report. Angiology 2002; 53 (4): 471-474
294. Danenberg HD, Hasin Y. Polymorphic ventricular tachycardia and repolarization abnormalities accompanying intracerebral hemorrhage. Circulation 2000; 101 (6): E81
295. Alehan D, Ceviz N, Celiker A. Torsade de pointes associated with encephalitis. Turk J Pediatr 1999; 41 (3): 395-398
296. Goldenberg I, Moss AJ. Long QT syndrome. J Am Coll Cardiol 2008; 51 (24): 2291-2300
297. Trejbal K, Mitro P. ECG changes in alcoholic intoxication. Vnitr Lek 2008; 54 (4): 410-414
298. Anand S, Singh S, Nahar Saikia U, et al. Cardiac abnormalities in acute organophosphate poisoning. Clin Toxicol (Phila) 2009; 47 (3): 230-235
299. De Ponti F, Poluzzi E, Cavalli A, et al. Safety of nonantiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002; 25 (4): 263-286
300. Di Micoli A, Zambruni A, Bracci E, et al. "Torsade de pointes" during amiodarone infusion in a cirrhotic woman with a prolonged QT interval. Dig Liver Dis 2009; 41 (7): 535-538
301. Schattner A, Gindin J, Geltner D. Fatal torsade de pointes following jaundice in a patient treated with disopyramide. Postgrad Med J 1989; 65 (763): 333-334
302. Reiffel JA, AppelG. Importance ofQT interval determination and renal function assessment during antiarrhythmic drug therapy. J Cardiovasc Pharmacol Ther 2001; 6 (2): 111-119
303. Rottlaender D, Hoppe UC. Risks of non-prescription medication. Clobutinol cough syrup as a recent example. Dtsch Med Wochenschr 2008; 133 (4): 144-146
304. Piccirillo G, Magri D, Matera S, et al. Effects of pink grapefruit juice on QT variability in patients with dilated or hypertensive cardiomyopathy and in healthy subjects. Transl Res 2008; 151 (5): 267-272
305. Schrickel J, Bielik H, Yang A, et al. Amiodarone-associated "torsade de pointes": relevance of concomitant cardiovascular medication in a patient with atrial fibrillation and structural heart disease. Z Kardiol 2003; 92 (10): 889-892
306. Singh BN, Gaarder TD, Kanegae T, et al. Liquid protein diets and torsade de pointes. JAMA 1978; 240 (2): 115-119
307. Chen IC, Chang KC, Hsieh YK, et al. Torsade de pointes due to consumption of Sauropus androgynus as a weight-reducing vegetable. Am J Cardiol 1996; 78 (10): 1186-1187
308. Marinucci P. Risk of torsades de pointes with non-cardiac drugs: grapefruit juice is source of potentially life threatening adverse drug reactions. BMJ 2001; 322 (7277): 47
309. Sagir A, Schmitt M, Dilger K, et al. Inhibition of cytochrome P450 3A: relevant drug interactions in gastro-enterology. Digestion 2003; 68 (1): 41-48
310. Isner JM, Roberts WC, Heymsfield SB, et al. Anorexia nervosa and sudden death. Ann Intern Med 1985; 102 (1): 49-52
311. Suri R, Poist ES, Hager WD, et al. Unrecognized bulimia nervosa: a potential cause of perioperative cardiac dys-rhythmias. Can J Anaesth 1999; 46 (11): 1048-1052
312. Pringle TH, Scobie IN, Murray RG, et al. Prolongation of the QT interval during therapeutic starvation: a substrate for malignant arrhythmias. Int J Obes 1983; 7 (3): 253-261
313. Kocheril AG, Bokhari SA, Batsford WP, et al. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 1997; 20 (11): 2810-2816
314. Paran Y, Mashav N, Henis O, et al. Drug-induced torsades de pointes in patients aged 80 years or more. Anadolu Kardiyol Derg 2008; 8 (4): 260-265
315. Hermans K, Stockman D, Van den Branden F. Grapefruit and tonic: a deadly combination in a patient with the long QT syndrome. Am J Med 2003; 114 (6): 511-512
316. Wilcock A, Beattie JM. Prolonged QT interval and methadone: implications for palliative care. Curr Opin Support Palliat Care 2009; 3 (4): 252-257
317. von Moltke LL, Greenblatt DJ, Duan SX, et al. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994; 34 (12): 1222-1227
318. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electro-cardiographic consequences. JAMA 1993; 269 (12): 1513-1518
319. Thanacoody RH, Daly AK, Reilly JG, et al. Factors affecting drug concentrations and QT interval during thiori-dazine therapy. Clin Pharmacol Ther 2007; 82 (5): 555-565
320. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348 (19): 1866-1874
321. Bednar MM, Harrigan EP, Ruskin JN. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 2002; 89 (11): 1316-1319
322. Johnson JN, Ackerman MJ. QTc: how long is too long? Br J Sports Med 2009; 43 (9): 657-662
323. Viskin S. The QT interval: too long, too short or just right. Heart Rhythm 2009; 6 (5): 711-715
324. Shah RR. Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance. Drug Saf 2007; 30 (12): 1093-1110
325. Fabritz L, Breithardt G, Kirchhof P. Preclinical testing of drug-induced proarrhythmia: value of transgenic models. Cardiovasc Hematol Agents Med Chem 2007; 5 (4): 289-94